Skip to Content
Merck
All Photos(1)

Key Documents

05-212

Sigma-Aldrich

Anti-PI3 Kinase Antibody, p85, N-SH3, clone AB6

clone AB6, Upstate®, from mouse

Synonym(s):

PI3-kinase p85 subunit alpha, PtdIns-3-kinase p85-alpha, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85

alpha), phosphatidylinositol 3-kinase, regulatory, 1, phosphatidylinositol 3-kinase-associated p-85 alpha, phosphoinos

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

AB6, monoclonal

species reactivity

human, rat, mouse

manufacturer/tradename

Upstate®

technique(s)

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG1κ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... PIK3R1(5295)

General description

The enzyme phosphatidylinositol 3 kinase (PI3 kinase) is a lipid kinase that is thought to phosphorylate second messengers in growth signaling pathways. PI3K exists as a heterodimer of catalytic 110 kDa (p110) and regulatory 85 kDa (p85, p50 or p55) subunits. The p85 unit consists of two closely related proteins: p85 alpha, which binds tightly to the catalytic subunit and p85 beta, a protein of unknown function. They share 62% amino acid sequence identity. p85 alpha lacks PI3 kinase activity, but may serve as regulator of the catalytic subunit, p110, by acting as the link between PI3K and the ligand activated receptor. Both isoforms bind to activated receptors and serve as tyrosine kinase substrates.

Specificity

This antibody recognizes p85 alpha subunit of PI3 Kinase; does not recognize p85 beta subunit.

Immunogen

Recombinant human p85 alpha PI3 Kinase expressed in E. Coli. Clone AB6.

Application

Immunocytochemistry:
10 µg/mL of a previous lot of this antibody was used in immunocytochemistry.

Immunoprecipitation:
4 µg of a previous lot immunoprecipitated PI3 Kinase from 500 µg of an A431 RIPA lysate, as confirmed by immunoblot using a polyclonal PI3 Kinase antibody (Catalog # 06-195).
Research Category
Signaling
Research Sub Category
PI3K, Akt, & mTOR Signaling

Kinases & Phosphatases
This Anti-PI3 Kinase Antibody, p85, N-SH3, clone AB6 is validated for use in IC, IP, WB for the detection of PI3 Kinase.

Quality

Routinely evaluated by Western Blot on RIPA lysates from human A431 cells, or RIPA lysates from rat L6 myoblasts.

Western Blot Analysis:
0.5-2 µg/mL of this lot detected PI3 Kinase in RIPA lysates from human A431 cells; previous lots detected PI3 Kinase in RIPA lysates from rat L6 myoblasts.

Target description

85 kDa

Linkage

Replaces: 04-403

Physical form

Format: Purified
Protein A chromatography
Purified mouse monoclonal IgG1κ in buffer containing PBS, pH 7.2 with 50% glycerol.

Storage and Stability

Stable for 1 year at -20°C from date of receipt.

Handling Recommendations:
Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20ºC. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20ºC may cause glycerol-containing solutions to become frozen during storage.

Analysis Note

Control
Positive Antigen Control: Catalog #12-301, non-stimulated A431 cell lysate. Add 2.5µL of 2-mercaptoethanol/100µL of lysate and boil for 5 minutes to reduce the preparation. Load 20µg of reduced lysate per lane for minigels.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Differential activation of phospholipase C-gamma 1 and mitogen-activated protein kinase in naive and antigen-primed CD4 T cells by the peptide/MHC ligand
Ericsson, P. O., et al
Journal of immunology (Baltimore, Md. : 1950), 156, 2045-2053 (1996)
Kianoush Khaleghpour et al.
Carcinogenesis, 25(2), 241-248 (2003-10-28)
The phosphoinositide 3-kinase (PI 3-kinase) signaling pathway has been shown to play a pivotal role in intracellular signal transduction pathways involved in cell growth, cellular transformation and tumorigenesis. Analysis of several colon adenocarcinoma cell lines indicates that the PI 3-kinase
Victoria A Elliott et al.
PloS one, 9(5), e97432-e97432 (2014-05-16)
Liver metastasis is the most common cause of death in patients with colorectal cancer. Despite extensive research into the biology of cancer progression, the molecular mechanisms that drive colorectal cancer metastasis are not well characterized. HT29 LM1, HT29 LM2, HT29
Jose Mercado-Matos et al.
Molecular and cellular biology, 38(14) (2018-04-25)
Although the insulin receptor substrate (IRS) proteins IRS1 and IRS2 share considerable homology and activate common signaling pathways, their contributions to breast cancer are distinct. IRS1 has been implicated in the proliferation and survival of breast tumor cells. In contrast
Coralie Poulard et al.
International journal of molecular sciences, 20(11) (2019-06-15)
Endocrine therapies targeting oestrogen signalling have significantly improved breast cancer management. However, their efficacy is limited by intrinsic and acquired resistance to treatment, which remains a major challenge for oestrogen receptor α (ERα)-positive tumours. Though many studies using in vitro

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service